{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T04:58:19Z","timestamp":1711169899855},"reference-count":31,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DD&amp;T"],"published-print":{"date-parts":[[2021,10,31]]},"DOI":"10.5582\/ddt.2021.01083","type":"journal-article","created":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T22:08:36Z","timestamp":1635372516000},"page":"241-247","source":"Crossref","is-referenced-by-count":2,"title":["Physicochemical properties of brand and generic infusion fluid preparations (Part 3): Investigation of type 1 hypotonic infusion fluids"],"prefix":"10.5582","volume":"15","author":[{"given":"Sawako","family":"Takei","sequence":"first","affiliation":[{"name":"Center for Experimental Pharmacy Practice, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soh","family":"Katsuyama","sequence":"additional","affiliation":[{"name":"Clinical Pharmaceutical Sciences Course, Department of Pharmaceutical Sciences, Nihon Pharmaceutical University, Kitaadachi-gun, Saitama Prefecture, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Hori","sequence":"additional","affiliation":[{"name":"Center for Experimental Pharmacy Practice, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3542","reference":[{"key":"1","unstructured":"1. Ministry of Health, Labor and Welfare. Basic policy on economic and fiscal management and reform 2017. <i>https:\/\/www5.cao.go.jp\/keizai-shimon\/kaigi\/cabinet\/2017\/decision0609.html <\/i>(accessed October 8, 2021). (in Japanese)"},{"key":"2","unstructured":"2. Ministry of Health, Labor and Welfare. 4. Percentage of generic drugs used by each insurer, (as of March 2021). <i>https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/0000190726.html<\/i> (accessed October 8, 2021). (in Japanese)"},{"key":"3","unstructured":"3. Medical Division, Insurance Bureau, Ministry of Health, Labor and Welfare. About the 2016 drug price system reform. <i>https:\/\/www.mhlw.go.jp\/file\/06-Seisakujouhou-12400000-Hokenkyoku\/0000114391.pdf<\/i> (accessed October 8, 2021). (in Japanese)"},{"key":"4","unstructured":"4. Ministry of Health, Labor and Welfare. List of items listed in NHI price standards and information on generic drugs (until March 31, 2nd year of Reiwa) 2 injections. <i>https:\/\/www.mhlw.go.jp\/topics\/2019\/08\/tp20190819-01.html<\/i> (accessed October 8, 2021). (in Japanese)"},{"key":"5","unstructured":"5. Ministry of Health, Labor and Welfare. List of items listed in NHI price standards and information on generic drugs (until March 31, 2nd year of Reiwa). List of basic drugs, etc. for which modified dispensing is permitted as with generic drugs. <i>https:\/\/www.mhlw.go.jp\/topics\/2019\/08\/tp20190819-01.html<\/i> (accessed October 8, 2021). (in Japanese)"},{"key":"6","unstructured":"6. Japan Generic Pharmaceutical Association. Generic drug Q &amp; A. <i>https:\/\/www.jga.gr.jp\/medical\/faq.html<\/i> (accessed October 8, 2021). (in Japanese)"},{"key":"7","unstructured":"7. Takei S, Ohara H, Kageyama M, Tobari H, Besshoh S, Hamada M, Inoue M, Samizo K, Kuramoto K. Investigation into the physicochemical quality of original and generic infusion fluid preparation (1). J Drug Interact Res. 2016; 39:135-144. (in Japanese)"},{"key":"8","unstructured":"8. Takei S, Ohara H, Kageyama M, Tobari H, Besshoh S, Hamada M, Masuda T, Ohyama K, Katsuyama S, Inoue M, Kuramoto K. Investigation into the physicochemical quality of original and generic infusion fluid preparations (2): Investigation on the maintenance fluid (No.3). Jpn Soc Clin Info Parenteral Drugs. 2017; 6:25-35. (in Japanese)"},{"key":"9","unstructured":"9. Generic Drug Quality Information Study Group. List of data sheets for the latest quality information on medical drugs (BlueBook). <i>https:\/\/www.nihs.go.jp\/drug\/ecqaged\/bluebook\/list.html<\/i> (accessed October 8, 2021). (in Japanese)"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Falchuk KH, Peterson L, McNeil BJ. Microparticulate-induced phlebitis. Its prevention by in-line filtration. N Engl J Med. 1985; 312:78-82.","DOI":"10.1056\/NEJM198501103120203"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Tang TT, Chambers CH, Gallen WJ, McCreadie SR. Pulmonary fiber embolism and granuloma. JAMA. 1978; 239:948-950.","DOI":"10.1001\/jama.239.10.948"},{"key":"12","unstructured":"12. Ministry of Health, Labor and Welfare. The Japanese Pharmacopoeia 18th edition, General test method. Osmotic pressure measurement method. p. 59.<i> https:\/\/www.mhlw.go.jp\/content\/11120000\/000788359.pdf <\/i>(accessed October 8, 2021). (in Japanese)"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Sakai M, Ikesue H, Yamamoto K, Tomiyoshi Y, Kokubu C, Grimm R, Takada A, Sonoda M, Kawashige M, Egashira N, Oishi R. Analysis of questions on drug use and answers to them to clarify healthcare professionals&apos; needs for drug information, and application of findings. Jpn J Pharm Health Care Sci. 2009; 35:161-166. (in Japanese)","DOI":"10.5649\/jjphcs.35.161"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Konomura K, Kanai N, Ueda A, Kusama M, Akazawa M. A survey on hospital formulary development in Japan in 2015. Jpn J Clin Pharmacol Ther. 2016; 47:189-199. (in Japanese)","DOI":"10.3999\/jscpt.47.189"},{"key":"15","unstructured":"15. Tokyo Metropolitan Health and Welfare Bureau. Results of questionnaire on generic drugs. <i>https:\/\/www.fukushihoken.metro.tokyo.lg.jp\/iryo\/kokuho\/kohatsuanshin\/kohatsuchosa.files\/hokokusyo.pdf <\/i>(accessed October 8, 2021). (in Japanese)"},{"key":"16","unstructured":"16. Sugiura S. Acidosis caused by high-calorie infusion. Pharmaceuticals. 1998; 40:1096-1102."},{"key":"17","unstructured":"17. Ministry of Health, Labor and Welfare, Pharmaceutical Safety and Environmental Health Bureau. Jun. 8, 2017. Yakuseianhatu No.1. Notes on the description procedure of package inserts for medical drugs.<i> https:\/\/www.mhlw.go.jp\/web\/t_doc?dataId=00tc2704&amp;dataType=1&amp;pageNo=1<\/i> (accessed October 8, 2021). (in Japanese)"},{"key":"18","unstructured":"18. Costanzo LS. Physiology, 6th Edition. In: Acid-base Physiology, Metabolic Acidosis (Elyse OG, Jennifer E, Daniel F, eds.). Elsevier, Tokyo, Japan, 2019; pp. 312, 328-330."},{"key":"19","unstructured":"19. Yasuhiko I. Blood Gases at a Glance. 2nd edition. In: Adjustment of acid-base balance. Medical Sciences International, Ltd., ed., Tokyo, Japan, 2013; Ch. 4, pp. 40-41.(in Japanese)"},{"key":"20","unstructured":"20. AstraZeneca MediChannel. Omeprazole injection interview form. p. 8. <i>http:\/\/med.astrazeneca.co.jp\/product\/OMP.html<\/i> (accessed October 8, 2021)."},{"key":"21","unstructured":"21. Maruishi Pharmaceutical Co., Ltd. Site for medical professionals, Product information, Dorumcam<sup>\u00ae<\/sup> Injection 10 mg Interview Form. p. 5.<i> https:\/\/www.maruishi-pharm.co.jp\/medical\/search\/<\/i> (accessed October 8, 2021). (in Japanese)"},{"key":"22","unstructured":"22. Akase T, Nakamura H. Thushayaku Yueki no haigohhenka, Ver. 2. In: pH variation test. Yodosha Ltd., ed., Tokyo, Japan. 2017; Ch 3, pp. 47-49. (in Japanese)"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Gazitua R, Wilson K, Bistrian BR, Blackburn GL. Factors determining peripheral vein tolerance to amino acid infusions. Arch Surg. 1979; 114:897-900.","DOI":"10.1001\/archsurg.1979.01370320029005"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Katsuyama S, Kuramoto K, Hamad S, Shoji T, Nakagawa Y. Tissue distribution of particulates administered intravenously. Jpn J Pharm Health Care Sci. 2007; 33:510-514. (in Japanese)","DOI":"10.5649\/jjphcs.33.510"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Sugahara T, Kotani M, Kuramoto K, Arai K, Siraishi T, Shoji T. Tissue distribution of intravenously administered insoluble microparticles: Report II. Jpn J Pharm Health Care Sci. 2012; 38:559-567. (in Japanese)","DOI":"10.5649\/jjphcs.38.559"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Yorioka K, Oie S, Oomaki M, Imamura A, Kamiya A. Particulate and microbial contamination in in-use admixed intravenous infusions. Biol Pharm Bull. 2006; 29:2321-2323.","DOI":"10.1248\/bpb.29.2321"},{"key":"27","unstructured":"27. Sugahara T, Kuramoto K, Suzuki H, Shiraishi T, Ishii K, Tamachi M, Shoji T. Usefulness of in-line filters for removal of insoluble microparticles. Jpn Soc Clin Nutr Metab. 2010; 25:1243-1250. (in Japanese)"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Perez M, D\u00e9caudin B, Chahla WA, Nelken B, Storme L, Masse M, Barth\u00e9l\u00e9my C, Lebuffe G, Odou P. Effectiveness of in-line filters to completely remove particulate contamination during a pediatric multidrug infusion protocol. Sci Rep. 2018; 8:7114.","DOI":"10.1038\/s41598-018-25602-6"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Schmitt E, Meybohm P, Herrmann E, Ammersbach K, Endres R, Lindau S, Helmer P, Zacharowski K, Neb H. In-line filtration of intravenous infusion may reduce organ dysfunction of adult critical patients. BMC Critical Care. 2019; 23:373.","DOI":"10.1186\/s13054-019-2618-z"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Sato T, Teshima D, Sendo T, Hirakawa M, Nakao Y, Kataoka Y, Oishi R. Influence of in-line filtration in the delivery of fat emulsion. Jpn J Hosp Pharm. 1998; 24:277-283. (in Japanese)","DOI":"10.5649\/jjphcs1975.24.277"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Yago K, Mastubara H, Otori K, Sakuma M, Shimada S. Adsorption of rhG-CSF to various intravenous filters (2). Jpn J Hosp Pharm. 1998; 24:697-703. (in Japanese)","DOI":"10.5649\/jjphcs1975.24.697"}],"container-title":["Drug Discoveries &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/15\/5\/15_2021.01083\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T03:55:47Z","timestamp":1637985347000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/15\/5\/15_2021.01083\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,31]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.5582\/ddt.2021.01083","relation":{},"ISSN":["1881-7831","1881-784X"],"issn-type":[{"value":"1881-7831","type":"print"},{"value":"1881-784X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,31]]},"article-number":"2021.01083"}}